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Significance {#sec1}
============

**Targeted therapies are now being developed for a subset of neuroblastomas with ALK mutations. However, MYCN pathway inhibitors have proved difficult to develop. We demonstrate that the presence of *MYCN* amplification in neuroblastoma exhibits synthetic lethality when treated with the BCL-2 targeting agent ABT-199, and that these tumors are further sensitized by the addition of the Aurora A inhibitor, MLN8237, in cell culture models and diverse mouse models. In contrast, *MYCN*-WT neuroblastoma cell culture models and human xenografts proved insensitive to this combination. Therefore, exploiting the paradoxical apoptosis-promoting function of *MYCN* amplification in neuroblastoma could be an effective strategy for the development of better therapies. ABT-199/MLN8237 combination therapy is differentially effective in the high-risk, *MYCN*-amplified subset of neuroblastoma.**

Introduction {#sec2}
============

There are now a number of successful targeted therapies that treat genetically distinct cancers (reviewed in [@bib24]). Unfortunately, many cancer subtypes are not yet amenable to targeted therapy treatment, including cancers with well-defined driver oncogenes. For example, *KRAS* mutations are found at high rates in lung, colorectal, and pancreatic cancer, and inhibiting KRAS in these cancers causes tumor growth inhibition ([@bib55], [@bib64]). However, KRAS, like most non-kinase driving oncogenes, is not currently pharmacologically targetable. Alternative means of blocking KRAS, such as synthetic lethal approaches or combined inhibition of important downstream pathways, are being pursued to treat these cancers (reviewed in [@bib36]).

Neuroblastoma is a neural-crest-derived cancer and is the leading cause of cancer-related deaths in children aged 1--4 years ([@bib13]). High-level amplifications of the *MYCN* oncogene is observed in about 20% of cases, and has long been associated with high-risk disease and poor outcome in neuroblastoma ([@bib23]). *MYCN* encodes an E-BOX-binding, basic-helix-loop-helix-leucine zipper (bHLH-LZ) transcription factor that is enriched in the nervous system. In these cancers, *MYCN* is a bona fide oncogenic driver ([@bib3], [@bib61]) and, similar to KRAS in KRAS-driven tumors, preclinical inhibition of MYCN protein leads to tumor growth inhibition in neuroblastoma mouse models ([@bib2], [@bib3], [@bib8], [@bib11], [@bib16], [@bib45]). However, MYCN is not amenable to direct pharmacologic inhibition, and preclinical efficacy of indirectly targeting MYCN has largely been modest ([@bib2], [@bib5], [@bib16], [@bib45]). As such, augmenting treatment efficacy for this high-risk group will likely require the development of additional rational therapies based on targetable pathways specifically activated in neuroblastomas with *MYCN* amplification. To this point, while MYCN has the pro-growth and pro-survival characteristics of a classical oncogene, MYCN also has the ability to promote apoptosis ([@bib4], [@bib12], [@bib44], [@bib58]).

The Genomics of Drug Sensitivity in Cancer (GDSC) is a comprehensive drug susceptibility discovery program that we have developed to help identify therapeutic strategies for genetically defined subsets of cancer ([@bib14], [@bib63]). Previous studies building on the GDSC findings have revealed sometimes unsuspected susceptibilities, such as the sensitivity of Ewing sarcomas driven by a *EWS-FLI1* translocation to PARP inhibitors ([@bib14]), the response of *KRAS* and *BRAF* mutant colorectal cancers to simultaneous MCL-1/BCL-xL/BCL-2 inhibition ([@bib9]), and the response of *TP53*/*RB*-deleted small-cell lung cancers to the BH3 mimetic ABT-263 upon TORC1/2 inhibitor addition ([@bib10]). Here, we investigate potential therapeutic opportunities for *MYCN*-amplified neuroblastoma.

Results {#sec3}
=======

*MYCN*-Amplified Neuroblastoma Cells Are Highly Sensitive to ABT-263, due to High NOXA {#sec3.1}
--------------------------------------------------------------------------------------

Analysis of drug-sensitivity data of ∼500 solid tumor cancer cell lines from a high-throughput drug screen ([@bib14]) indicated that among all solid tumor types, neuroblastoma cell lines were exquisitely sensitive to the in-clinic BCL-2/BCL-2/xL inhibitor ABT-263 (navitoclax) ([Figure 1](#fig1){ref-type="fig"}A). Intriguingly, this sensitivity was specific only to neuroblastoma cells with *MYCN* amplification ([Figure 1](#fig1){ref-type="fig"}B). In fact, among 130 experimental and clinical drugs, *MYCN*-amplified cell lines (20/26 of which were neuroblastoma cell lines) showed the most significant shift in half maximal inhibitory concentration (IC~50~) toward sensitivity with ABT-263 than any other drug compared with *MYCN*-WT cell lines ([Table S1](#mmc1){ref-type="supplementary-material"}, top 39 by IC~50~ shift listed). To explore the underlying etiology for this exquisite sensitivity of *MYCN*-amplified cell lines, we examined expression levels of BCL-2 family members that are known to modulate the sensitivity to ABT-263 by interrogating a database of 20 *MYCN*-amplified and 81 *MYCN*-WT neuroblastoma primary tumors ([@bib59]). This analysis uncovered the MCL-1 inhibitor NOXA, encoded by *PMAIP1*, to be significantly higher in *MYCN*-amplified neuroblastomas ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). The paradoxical nature of *PMAIP1* upregulation in *MYCN*-amplified neuroblastoma is underscored by the fact that *PMAIP1* expression was sharply decreased in stage 4 *MYCN*-WT neuroblastomas compared with stage 1--3 *MYCN*-WT neuroblastomas ([Figure 1](#fig1){ref-type="fig"}E), consistent with the widely noted suppression of pro-apoptotic proteins as cancers progress (reviewed in [@bib20]). High expression of *PMAIP1* in the subset of *MYCN*-amplified neuroblastomas was confirmed in a second dataset of neuroblastomas ([@bib25]), again without differential expression of other key BCL-2 family members ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In addition, gene expression datasets from medulloblastoma tumors ([@bib27], [@bib43], [@bib48]), a pediatric cancer in which *MYCN* is often amplified ([@bib49]), indicated that *PMAIP1* mRNA expression positively correlated with *MYCN* mRNA expression ([Figures 1](#fig1){ref-type="fig"}F, [S1](#mmc1){ref-type="supplementary-material"}E, and S1F). The positive relationship between *PMAIP1* mRNA expression and *MYCN* mRNA expression was also observed in a large collection of neuroblastoma cell lines ([@bib14]) ([Figure S1](#mmc1){ref-type="supplementary-material"}G) and confirmed in our neuroblastoma cell line panel ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Altogether, these data indicate high MYCN expression is associated with high NOXA expression.

High levels of NOXA expression can confer sensitivity to BCL-2/BCL-xL inhibitors ([@bib29], [@bib40], [@bib41], [@bib60]), and artificial expression of NOXA is sufficient to sensitize cancer cells to BCL-2/BCL-xL inhibitors ([@bib40]), suggesting that increased NOXA expression is a contributing factor to ABT-263 sensitivity observed in *MYCN*-amplified neuroblastoma cells. We therefore reduced NOXA expression by stably expressing short hairpins (sh) against NOXA or transfection of siRNA directed against NOXA, with both experimental methods resulting in reduced NOXA expression and protection of *MYCN*-amplified neuroblastoma cell lines from ABT-263-mediated apoptosis compared with controls ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). These data confirm that reduction of NOXA levels de-sensitizes *MYCN*-amplified neuroblastoma cells to ABT-263.

The relationship between *MYCN* and *PMAIP1* expression in *MYCN*-amplified neuroblastoma cells was significant ([Figures 1](#fig1){ref-type="fig"}C--1E and [S1](#mmc1){ref-type="supplementary-material"}D, S1G, and S1H), raising the possibility that *MYCN* may regulate *PMAIP1* in these tumors. We investigated this hypothesis by knockdown of MYCN and found a concomitant decrease in NOXA protein ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C) and *PMAIP1* mRNA levels ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Furthermore, ectopic MYCN expression in *MYCN*-WT neuroblastoma cells or in epithelium-derived RPE-1 cells led to a concomitant increase in NOXA at both the protein and RNA levels ([Figures 2](#fig2){ref-type="fig"}D and 2E). In contrast, reducing MYCN levels in *MYCN*-amplified neuroblastoma cells or increasing MYCN in *MYCN*-WT neuroblastoma cells did not consistently affect the expression of other BCL-2 family proteins other than *PMAIP1* ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), nor did MYCN levels correlate with other BCL-2 family member expression in the Garnett cell line collection ([Figures S2](#mmc1){ref-type="supplementary-material"}G--S2I). These data indicate that *MYCN* amplification in neuroblastoma cells upregulates NOXA expression and contributes to ABT-263 sensitivity.

We further assessed whether MYCN was causative of ABT-263 sensitivity. Upon ABT-263 treatment, the exogenous MYCN-expressing WT neuroblastoma cells demonstrated a marked increase in cleaved PARP expression compared with the GFP-expressing controls; consistently, these cells had enhanced sensitivity to ABT-263 in 3-day viability assays ([Figures 2](#fig2){ref-type="fig"}F and 2G). Conversely, the shMYCN-transduced *MYCN*-amplified neuroblastoma SK-N-BE(2) and SK-N-DZ cells were de-sensitized to ABT-263 compared with the control cells ([Figures 2](#fig2){ref-type="fig"}H and 2I). These data further demonstrate a causal role of MYCN in ABT-263 sensitivity in neuroblastoma. We next probed whether MYCN-regulation of *PMAIP1* was direct. Chromatin immunoprecipitation assays revealed preferential binding of the MYCN antibody over an isotype-matched IgG control within the promoter of *PMAIP1* similar to well-characterized MYCN-binding sites in *MDM2* and *MIR17HG* ([Figure 2](#fig2){ref-type="fig"}J) ([@bib52], [@bib53]). One site, BS1, includes the reported MYCN-preferential *CATGTG* motif, and BS2 includes the *CAACTG* motif that MYCN shows a proclivity toward when amplified ([@bib39]). These data altogether demonstrate that amplified *MYCN* sensitizes neuroblastoma cells to ABT-263, and this involves MYCN-dependent upregulation of *PMAIP1* transcription.

*MYCN*-Amplified Neuroblastoma Cells Retain Sensitivity to ABT-199 {#sec3.2}
------------------------------------------------------------------

Despite its clinical efficacy in certain hematologic cancers, the utility of ABT-263 may be hampered by on-target thrombocytopenia ([@bib47]) that is a result of BCL-xL inhibition in platelets ([@bib34]). ABT-199 (venetoclax) is a next-generation BH3 mimetic designed to spare BCL-xL ([@bib54]); however, despite the obvious benefit of this drug in avoiding thrombocytopenia, its utility may largely be dictated by a cancer\'s propensity to rely on BCL-2 over BCL-xL for survival. Toward this end, we performed gene expression analysis of BCL-2 and BCL-xL in the Cancer Cell Line Encyclopedia ([@bib1]). BCL-2 expression was significantly higher in neuroblastoma cells compared with other solid tumor cell lines, and BCL-xL expression was significantly reduced in neuroblastoma cells, resulting in a high BCL-2:BCL-xL ratio ([Figure 3](#fig3){ref-type="fig"}A). We therefore hypothesized that the unique sensitivity to ABT-263 seen in *MYCN*-amplified cells would be preserved following ABT-199 treatment; in fact, we found that *MYCN*-amplified neuroblastoma cells remained sensitive to ABT-199, while *MYCN*-WT neuroblastoma cells and RPE-1 cells were insensitive to ABT-199, consistent with their insensitivity to ABT-263 ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A). In the other solid tumor cell lines with a range of sensitivity to ABT-263, all lines were resistant to ABT-199 ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A). Similar to the data with ABT-263 ([Figure 2](#fig2){ref-type="fig"}F), exogenous expression of MYCN markedly increased sensitivity to ABT-199 in *MYCN*-WT neuroblastoma cells and RPE-1 cells ([Figure 3](#fig3){ref-type="fig"}C).

Combination Drug Screen Reveals that Dual BCL-2-Aurora A Kinase Inhibition Therapy Is Effective {#sec3.3}
-----------------------------------------------------------------------------------------------

ABT-199 has exhibited a relatively favorable toxicity profile ([@bib51], [@bib30]), and it uniquely induced apoptosis in *MYCN*-amplified neuroblastoma cells ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A); we therefore decided to pursue the drug as part of a combination targeted therapy strategy for *MYCN*-amplified neuroblastoma. We performed a combination drug screen using ABT-199 as the "anchor" in combination with 24 targeted therapies covering a wide array of targets ([Table S2](#mmc1){ref-type="supplementary-material"}). We found that both concentrations of the Aurora A inhibitor MLN8237 (alisertib) and the Aurora A/B inhibitor VX680 (tozasertib) potently induced apoptosis in *MYCN*-amplified neuroblastomas when combined with ABT-199 ([Figures 4](#fig4){ref-type="fig"}A and 4B). Furthermore, both combinations potently decreased the viability of KELLY cells ([Figure 4](#fig4){ref-type="fig"}C), consistent with the apoptosis screen ([Figure 4](#fig4){ref-type="fig"}A); strong apoptotic responses were also detected when assayed by fluorescence-activated cell sorting (FACS) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). The Bliss independence model confirmed a marked synergistic interaction between MLN8237 and ABT-199 at relatively low concentrations of MLN8237 ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Consistent with the notion that both growth arrest and apoptosis are required for effective targeted therapy ([@bib9], [@bib19], [@bib20]), the addition of MLN8237 to ABT-199 resulted in growth arrest ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). These data indicate that Aurora A inhibition further sensitizes *MYCN*-amplified neuroblastoma cells to ABT-199.

Since MLN8237 showed single-agent activity in several neuroblastoma mouse xenograft models during experiments conducted by the Pediatric Preclinical Testing Program, leading to testing in pediatric neuroblastoma patients ([@bib33]), and MLN8237 was more potent at a lower dose than the dual Aurora inhibitor VX680 when combined with ABT-199 ([Figure 4](#fig4){ref-type="fig"}C), we decided to pursue ABT-199/MLN8237 combinations in *MYCN*-amplified neuroblastoma cells. MLN8237 is an in-clinic Aurora A inhibitor with high specificity over Aurora B ([@bib32]). We verified both single-agent efficacy of the two drugs as well as the apoptosis-inducing potency of the combination across a panel of *MYCN*-amplified neuroblastoma cells compared with both the *MYCN*-WT neuroblastoma cells and the RPE-1 cell line, where it was ineffective ([Figure 5](#fig5){ref-type="fig"}A, 57.6 ± 8.1 versus 5.8 ± 2.9, Student\'s *t* test, p = 0.0015).

MLN8237 Enhances ABT-199 Activity in Part through MCL-1 Reduction in *MYCN*-Amplified Neuroblastoma Cells {#sec3.4}
---------------------------------------------------------------------------------------------------------

We next sought to understand how the addition of MLN8237 further sensitized *MYCN*-amplified neuroblastoma cells to ABT-199. MLN8237 induced mitotic arrest ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B); interestingly, upon mitotic arrest, MCL-1 is phosphorylated and degraded in a proteasome-dependent manner ([@bib17], [@bib18], [@bib62]). In addition, much of targeted-therapy-induced apoptosis is ultimately controlled by a balance of expression and function of the BCL-2 family members ([@bib20]) and resistance to ABT-199 occurs through upregulation of BCL-xL and MCL-1 ([@bib6]). Since BCL-xL levels are relatively low in neuroblastoma ([Figure 3](#fig3){ref-type="fig"}A) and *MYCN*-amplified neuroblastoma cells and tumors have high levels of the MCL-1 inhibitor NOXA ([Figures 1](#fig1){ref-type="fig"}C--1E, [S1](#mmc1){ref-type="supplementary-material"}D, S1G, and S1H), we hypothesized that the further induction of apoptosis seen when MLN8237 was combined with ABT-199 could be due to reduction of MCL-1 levels, effectively decreasing the apoptotic threshold even lower in these cancers. Therefore, we assessed MCL-1 expression following MLN8237 treatment. We found that MCL-1 expression was downregulated following MLN8237 treatment ([Figure 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}C). Interestingly, we found levels of phosphorylated 4E-BP1 were also reduced by MLN8237, following the same pattern as MCL-1 expression and phosphorylated Aurora A ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}C). MCL-1 mRNA levels were elevated following treatment with MLN8237 ([Figure S4](#mmc1){ref-type="supplementary-material"}D), which may be a result of feedback from protein loss ([@bib9]). Furthermore, phosphorylated GSK3, corresponding to inactivation of the kinase, which stabilizes MCL-1 in a mitosis-independent matter ([@bib35]), was not inhibited by MLN8237, and in fact, was often upregulated ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

Inhibiting p4E-BP1 in other cancers leads to disruption of the eIF4G:eIF4E complex and downregulation of cap-dependent MCL-1 protein translation ([@bib31], [@bib37], [@bib50]), which suggested that MLN8237 reduced MCL-1 expression in *MYCN*-amplified neuroblastoma cells via a shift toward mitotic arrest-inducing degradation and away from cap-dependent MCL-1 translation. Therefore, we sought to determine whether inhibition of mTORC1-p4E-BP1 leads to downregulation of MCL-1 in these cancers ([@bib9], [@bib50]). In fact, we found that treatment with the TORC1/2 inhibitor MLN0128 led to downregulation of p-4E-BP1 and MCL-1 in *MYCN*-amplified neuroblastomas ([Figure S5](#mmc1){ref-type="supplementary-material"}A), which demonstrated that MCL-1 in these cancers is downregulated following inhibition of p4E-BP1. We verified that MLN8237 and VX680 treatment each resulted in loss of p4E-BP1 and MCL-1 in *MYCN*-amplified neuroblastoma cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B), as did knockdown of Aurora A ([Figure S5](#mmc1){ref-type="supplementary-material"}C). These data altogether confirm a role of Aurora A in the downregulation of p4E-BP1, which results in the downregulation of MCL-1 in *MYCN*-amplified neuroblastoma cells. We next treated *MYCN*-amplified neuroblastoma cells with a short time course of MLN8237, and found p4E-BP1 and MCL-1 were reduced prior to marked mitotic arrest ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E), suggesting a contribution of MCL-1 downregulation independent of mitotic arrest. To more directly address whether inhibition of protein translation contributes to MCL-1 downregulation following MLN8237 treatment, we first measured the effects of MLN8237 on global protein translation in *MYCN*-amplified neuroblastoma cells ([@bib15]). We demonstrate a consistent decrease in protein translation across the cells ([Figure S5](#mmc1){ref-type="supplementary-material"}F). To specifically determine whether inhibition of cap-dependent translation was contributing to the decrease in global protein synthesis, we performed a pull-down assay with m^7^-GTP Sepharose beads to determine whether the levels of cap-bound proteins were decreased. Western blot analysis revealed disassociation of eIF4G:eIF4E, significant for inhibition of cap-dependent protein translation ([Figure S5](#mmc1){ref-type="supplementary-material"}G), with the expected concomitant increase in 4EBP1:eIF4E complexes ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Therefore, in *MYCN*-amplified neuroblastoma, MLN8237 inhibits p4E-BP1, leading to loss of eIF4G:eIF4E complex-mediated MCL-1 protein translation.

We next sought to better define the role of MCL-1 in combination-induced toxicity. MCL-1 reduction by siRNA sensitized *MYCN*-amplified neuroblastoma cells to ABT-199, inducing similar levels of apoptosis as the combination treatment in the scrambled (sc) siRNA transfected cells ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}B). Introducing exogenous MCL-1 inhibited apoptosis, as measured by cleaved PARP induced by combined ABT-199/MLN8237 ([Figures 5](#fig5){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}A). The induction of apoptosis in *MYCN*-amplified neuroblastoma cells was mitigated by BIM siRNA ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}C), implicating that the disruption of BIM/MCL-1 complexes leads to loss of MCL-1-bound BIM and contributes to ABT-199/MLN8237-mediated apoptosis. To directly assess this, we performed immunoprecipitation with antibodies against MCL-1 and BIM in SK-N-BE(2) and SK-N-DZ cell lysates following different drug treatments. We found that BIM:MCL-1 complexes are increased following ABT-199 treatment, which mitigates BIM-mediated apoptosis; however, addition of MLN8237 markedly reduced these complexes, consistent with the effect of MLN8237 on MCL-1 expression in whole-cell extracts ([Figures 5](#fig5){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}D). These data altogether demonstrate that MLN8237 downregulation of MCL-1 contributes to the sensitivity of *MYCN*-amplified neuroblastoma cells to ABT-199/MLN8237 by disrupting BIM:MCL-1 complexes and that ABT-199/MLN8237 combination-induced apoptosis is, at least in part, mediated by BIM. Of interest, we found that MYCN protein levels were also reduced by MLN8237 treatment ([Figure 5](#fig5){ref-type="fig"}B), consistent with previous data ([@bib2]) and likely contributing to combination efficacy.

Differential Apoptosis Induced by ABT-199/MLN8237 in *MYCN*-Amplified Compared with *MYCN*-WT Neuroblastoma Cells Translates to Potent Differences in Drug Efficacy {#sec3.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To characterize the relevance of the differential apoptotic response seen in the combined ABT-199/MLN8237 treatment between *MYCN*-amplified and *MYCN*-WT neuroblastoma cells ([Figure 5](#fig5){ref-type="fig"}A), we treated cell lines with each inhibitor alone or in combination and assayed viability after 5 days ([Figures 5](#fig5){ref-type="fig"}F and 5G). After 5 days of treatment, cells treated with the combination demonstrated marked growth inhibition in the *MYCN*-amplified neuroblastoma cells compared with *MYCN*-WT cells; the single agents had limited and variable effects across the *MYCN*-amplified cell lines ([Figure 5](#fig5){ref-type="fig"}F). Consistent with the apoptosis data ([Figure 5](#fig5){ref-type="fig"}A), the combination had a limited effect on *MYCN*-WT neuroblastoma cells and the RPE-1 cell line ([Figure 5](#fig5){ref-type="fig"}G). Similarly, in 6-day viability assays, when cells were treated with increasing doses of MLN8237, the combination of ABT-199 and MLN8237 was markedly more effective in *MYCN*-amplified neuroblastoma cells compared with the *MYCN*-WT neuroblastoma cells and the RPE-1 cell line ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). It is noteworthy that similar levels of efficacy were demonstrated with the ABT-199/MLN8237 combination as the ABT-263/MLN8237 combination in the *MYCN*-amplified neuroblastoma cells ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). These data are consistent with the expression data supporting the use of the Bcl-xL-sparing ABT-199 in *MYCN*-amplified neuroblastoma ([Figure 3](#fig3){ref-type="fig"}A) and the ability of ABT-199 to induce apoptosis in these cancers ([Figure 3](#fig3){ref-type="fig"}B). Lastly, we noted that this combination was effective at even low concentrations of MLN8237 (10 nM MLN8237) in the *MYCN*-amplified neuroblastoma cells ([Figures 4](#fig4){ref-type="fig"}C, [5](#fig5){ref-type="fig"}F, and [S6](#mmc1){ref-type="supplementary-material"}E). Together, these data show a specific and potent in vitro efficacy of ABT-199/MLN8237 in *MYCN*-amplified neuroblastoma cells, even at relatively low concentrations of MLN8237.

ABT-199/MLN8237 Exhibits Robust In Vivo Activity against *MYCN*-Amplified Neuroblastoma {#sec3.6}
---------------------------------------------------------------------------------------

Based on the in vitro specificity and potency of this combination, we pursued studies in animal models of neuroblastoma. *MYCN*-amplified KELLY and SK-N-BE(2) xenograft-bearing mice were treated with 30 mg/kg once daily MLN8237, 100 mg/kg once daily ABT-199, or the combination, and tumor progression was monitored. There was no reduction in mouse body weight ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Neither MLN8237 nor ABT-199 alone regressed these tumors, whereas mice treated with the combination exhibited tumor regression ([Figure 6](#fig6){ref-type="fig"}A). KELLY xenografts in mice treated with the combination regressed to an undetectable level and remained undetectable for 60 days following the last treatment. Based on previous criteria ([@bib28]), we considered this a durable and lasting tumor-free response ([Figure 6](#fig6){ref-type="fig"}A). Analysis of tumors treated with MLN8237 and ABT-199 showed that the combination reduced the levels of MCL-1 and p4E-BP1 in vivo, consistent with our in vitro observations ([Figure 6](#fig6){ref-type="fig"}B). In contrast, the *MYCN*-WT SK-N-SH mouse xenograft model was insensitive, and in fact tumors treated with ABT-199 appeared to grow faster than the no-treatment controls ([Figure 6](#fig6){ref-type="fig"}C). Again, the combination therapy was well tolerated by evidence of weight sustainability ([Figure S7](#mmc1){ref-type="supplementary-material"}B). In vitro modeling of sensitivity to the combination revealed MYCN expression was sufficient to sensitize to the combination ([Figure 6](#fig6){ref-type="fig"}D), consistent with our data from the single-agent BCL-2 inhibitors ([Figures 2](#fig2){ref-type="fig"}F, 2G, [3](#fig3){ref-type="fig"}C).

MLN8237 has been tested in a phase I clinical trial conducted within the Children\'s Oncology Group ([@bib38]), which revealed an optimal dosing schedule of 80 mg/m^2^ daily for 7 days, followed by 14 days off treatment, repeated every 3 weeks. Therefore, we performed additional in vivo experiments at the clinically relevant dosing schedule ([@bib38]). In the *MYCN*-amplified human xenograft mouse model of NB-1643, ABT-199 was administered daily at 100 mg/kg, and MLN8237 was administered at 30 mg/kg, 7 days on, 14 days off. Following this dosing schedule, the NB-1643 model displayed tumor stasis with single-agent MLN8237 treatment, significant tumor regression with single-agent ABT-199 treatment, and complete regression of all tumors with the combination ([Figure 7](#fig7){ref-type="fig"}A); these mice were followed for an additional 60 days following completion of treatment, during which the tumors remained undetectable ([Figure 7](#fig7){ref-type="fig"}B).

The implementation of patient-derived cell lines and patient-derived xenografts (PDXs) in preclinical studies has been helpful to evaluate and improve cancer therapeutics ([@bib7], [@bib10]). Here, we have established *MYCN*-amplified neuroblastoma PDXs via injection of fresh tumor from a neuroblastoma patient into CB17 SCID mice for preclinical evaluation of this combination therapy. Following the same dosing schedule for MLN8237 of 1 week on, 2 weeks off, mice treated with 100 mg/kg once daily ABT-199, 30 mg/kg MLN8237, or the combination, were evaluated. While both single agents had modest activity in this model, the combination induced regression of ten out of ten tumors in the cohort ([Figure 7](#fig7){ref-type="fig"}C). In these PDXs, there was a notable increase in MCL-1 expression following ABT-199 treatment, and MLN8237 led to reduction in MCL-1 from both baseline levels and levels following ABT-199 treatment ([Figure 7](#fig7){ref-type="fig"}D), similar to the in vitro results ([Figure 5](#fig5){ref-type="fig"}B) and the KELLY tumors ([Figure 6](#fig6){ref-type="fig"}B). The combination-treated mice showed no reduction in weight gain during the treatment period ([Figure S7](#mmc1){ref-type="supplementary-material"}C), consistent with the mice from the Nu/Nu mouse studies ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). These data suggest that the combination therapy can induce sustained remissions in a PDX model harboring *MYCN* amplification using a clinically feasible schedule of MLN8237 and ABT-199 administration, supporting its promising preclinical profile and proposed mode of action ([Figure 8](#fig8){ref-type="fig"}).

Discussion {#sec4}
==========

Amplification of *MYCN* is the driving oncogenic event in a subset of the most aggressive neuroblastomas; exposure to MYCN antisense oligonucleotides results in tumor growth inhibition ([@bib3]). As a non-kinase, however, drugging MYCN with small molecule inhibitors has proven challenging. Recently, several groups reported that indirectly targeting MYCN resulted in anti-tumor activity, further validating the pathway as an important target ([@bib5], [@bib16], [@bib45]). One such approach used MLN8237, which induces proteasome-mediated degradation of MYCN ([@bib2]) and leads to loss of its expression ([@bib2]).

In this study, we took a pharmacogenomic approach to identify an effective combination-based targeted therapy for *MYCN*-amplified neuroblastoma. This approach yielded several important findings. First, *MYCN*-amplified neuroblastoma cells are exquisitely sensitive to the BCL-2/BCL-xL inhibitor ABT-263. MYCN directly regulates the expression of NOXA in these cancers, with amplified *MYCN* leading to high expression of NOXA. Second, due to high BCL-2/BCL-xL ratios in these cancers, *MYCN*-amplified neuroblastoma cells retain sensitivity to the BCL-2 inhibitor ABT-199. Third, the Aurora Kinase A inhibitor MLN8237 enhances efficacy of ABT-199 in part by inducing mitotic arrest and downregulating MCL-1, disrupting ABT-199 induced BIM:MCL-1 complexes. Fourth, in multiple mouse models of *MYCN*-amplified neuroblastoma, complete and sustained regressions were noted, without any overt signs of toxicity to the mice.

MYCN is a promiscuous transcription factor that prefers *CATGTG* and *CACGTG* E-BOX sites; moreover, amplified *MYCN* binds additional E-BOX sites, including a propensity towards *CAACTG* ([@bib39]). Here, we found that MYCN bound two regions in the *PMAIP1* promoter, encompassing a *CATGTG* E Box and a *CAACTG* E Box.

MYCN-induced upregulation of NOXA in neuroblastoma models adds to the list of other *MYCN*-regulated pro-apoptotic processes in this disease ([@bib4], [@bib12], [@bib44], [@bib58]). Debatin and colleagues demonstrated that while overexpression of MYCN in neuroblastoma does not induce apoptosis, it primes the cell for cytotoxic drugs to induce apoptosis through cooperative upregulation of BAX ([@bib12]). Therefore, it is likely that *MYCN*-driven anti-apoptotic signals are particularly critical for tumorigenesis in neuroblastoma in order to counter these pro-apoptotic signals ([@bib21]). For instance, caspase 8 is often silenced in neuroblastoma, and in TH-MYCN mice, which express MYCN in neural crest cells that form neuroblastomas; caspase 8 deficiencies cause formation of metastatic neuroblastomas in the bone marrow ([@bib56]). Consistent with a role of amplified *MYCN* in BCL-2 family-mediated apoptosis following cellular stress, BCL-2 overexpression from serum deprivation and metabolic stress can counter *MYCN*-mediated apoptotic signaling in neuroblastoma and, therefore, cooperate in tumorigenicity ([@bib26], [@bib57]). In addition, *MYCN* amplification participates in killing of neuroblastoma cells following glutamine deprivation, and this pathway involves NOXA ([@bib46]).

In our therapeutic approach, ABT-199 eliminates this pro-survival BCL-2 signal, thus allowing for MYCN-mediated pro-apoptotic signaling to help push the neuroblastoma cells toward the apoptotic threshold. MLN8237 further pushes the neuroblastoma cell past the apoptotic threshold through reduction of MCL-1; BCL-xL is ineffective at blocking the ensuing death signal because BCL-xL levels are markedly low. The benefit of MYCN reduction by MLN8237 outweighs any relief of a pro-apoptotic signal, consistent with the anti-cancerous effects of targeting MYCN alone in *MYCN*-amplified neuroblastoma. Altogether, the combination therapy reduces cell viability and induces widespread apoptosis in vitro, with in vivo tumor regressions demonstrated in preclinical models. Finally, since drug treatments were well tolerated in multiple mouse strains, the combination therapy appears to have a favorable toxicity profile.

Prolonged mitotic arrest leads to loss of MCL-1 ([@bib17], [@bib18]), as does downregulation of p-4E-BP1, which mediates eIF4 complex formation and subsequent cap-dependent translation ([@bib9], [@bib10], [@bib22], [@bib31], [@bib37], [@bib50]). Here, we have demonstrated that Aurora A inhibition not only leads to mitotic arrest but also leads to loss of p4E-BP1 in *MYCN*-amplified neuroblastoma cells (resulting in downregulation of MCL-1 as a result of cap-dependent translation inhibition). Therefore, it is likely that both mitotic arrest and loss of p4E-BP1-mediated cap-dependent protein translation contribute to the loss of MCL-1 following MLN8237 treatment in *MYCN*-amplified neuroblastoma cells.

To substantiate our in vitro and in vivo human xenograft findings, we found that the combination is effective in a *MYCN*-amplified neuroblastoma PDX model, which demonstrated only modest single-agent MLN8237 activity, mirroring clinical activity of MLN8237 in neuroblastoma ([@bib38]). Altogether, this combination should be prioritized for clinical testing in patients with the *MYCN*-amplified subset of neuroblastoma.

Experimental Procedures {#sec5}
=======================

Drug Screen {#sec5.1}
-----------

The drug screen in which the ABT-263 sensitivity data was obtained ([Figures 1](#fig1){ref-type="fig"}A and 1B) comparing neuroblastoma sensitivity with other solid tumor cell lines has been described previously ([@bib14]).

Targeted Therapy Anchor Screen {#sec5.2}
------------------------------

SK-N-DZ and KELLY cells were plated at 2,000 cells/well in 96-well plates in RPMI medium containing 10% fetal bovine serum. Cells were treated with either 1 μM ABT-199, 50 μM Z-FAD-FMK caspase inhibitor, 1 μM ABT-199 and 70 nM test drug, or 1 μM ABT-199 and 700 nM test drug. After 24 hr, caspase-3/7 levels were determined using the Caspase-Glo 3/7 Assay (Promega) following the manufacturer\'s instructions. Briefly, plates were allowed to equilibrate to room temperature and an equal volume of Caspase-Glo 3/7 Reagent was added to each well. Plates were mixed at 500 rpm for 30 s, incubated at room temperature, and luminescence read after 30 min.

Chromatin Immunoprecipitation {#sec5.3}
-----------------------------

Chromatin from ∼25 × 10^6^ KELLY and SK-N-DZ cells were purified and sheared on a Diagenode Bioruptor. Cycle thresholds reached from SYBR green incorporation were calculated from 5 ng of chromatin per qPCR reaction. Primers were BS1, 5-tgctgggattacagacgtga-3′ (forward), gagttcgagaccagcctgac (reverse), originally described in [@bib42]; BS2, 5-caggttcaagcgattctcgt-3′ (forward), ataccagccttgccaatatg-3 (reverse); MDM2, 5-agcctttgtgcggttcgtg-3′ (forward), 5-ccccgtgacctttaccctg-3′ (reverse); *MIR17HG*, 5-tctcccgagggcgagagttaaagc-3′ (forward), 5-caccctcgcgcgtacaaagtttgg-3′ (reverse).

Xenograft Studies {#sec5.4}
-----------------

Nu/Nu mice were injected with ∼5 × 10^6^ cells/100 μl of PBS, in combination with 100 μl of Matrigel. Mice were injected subcutaneously and monitored for tumor growth. When tumors reached ∼200--400 mm^3^, the tumor-bearing-mice were randomized to a no-treatment control group, a MLN8237 group (30 mg/kg), an ABT-199 group (100 mg/kg), or a combination group (same doses). Mice in the treatment cohorts (n = 3--6) were subsequently treated with drugs directly to the stomach by oral gavage. The solvent for MLN8237 was 10% 2-hydroxypropyl-β-cyclodextrin and 1% Na butyrate. The solvent for ABT-199 was 60% Phosal, 30% PEG 400, 10% EtOH. During the study, tumors were routinely measured by electronic caliper two to three times a week, in two dimensions (length and width), and with the formula v = l × (w)^2^(π/6), where v is the tumor volume, l is the length, and w is the width. The drug schedules were once daily for the different xenograft models except NB-1643, which was once daily for MLN8237 for 1 week, with 2 weeks off MLN8237, and MLN8237 treatment resuming on week 4. For pharmacodynamic studies, tumor-bearing mice were treated for 3 days, tumors were harvested ∼2--3 hr following the last treatment, and tumors were snap frozen in liquid nitrogen. All these mouse experiments were approved and performed in accordance with the Institutional Animal Care and Use Committee at the Massachusetts General Hospital.

Patient-Derived Xenografts {#sec5.5}
--------------------------

The PDX tumor tissue was obtained through the Children\'s Oncology Group Cell Culture and Xenograft Repository. CB17 SCID mice were subcutaneously implanted with *MYCN*-amplified COG-N-471x PDX tumors and monitored for tumor growth. Once the tumors reached a median tumor volume of 230--240 mm^3^, PDX-bearing mice were randomized into statistically identical cohorts (10 mice/group) and treated continuously with 100 mg/kg once daily of ABT-199; 30 mg/kg once daily of MLN8237 for 1 week, followed by 2 weeks without treatment and the cycle resumed on week 4; the combination of ABT-199 100 mg/kg once daily being given continuously with the MLN8237 30 mg/kg once daily dosed for 1 week with 2 weeks break; appropriate vehicle control of 60% Phosal50, 30% PEG400, 10% EtOH as ABT-199 vehicle and 10% hydroxypropyl-β-cyclodextrin, 1% Na butyrate as vehicle for MLN8237 by oral gavage in 100 μl/10 g of body weight. Tumor size was measured by caliper every 3--4 days, and volume was calculated by the spheroid formula: (p/6) × d^3^, where d represents the mean diameter. The work on the PDX is considered non-human subjects research. All animal experiments were conducted according to relevant national and international guidelines. The PDX study in CB17 SCID mice was approved by the Children\'s Hospital of Philadelphia Institutional Animal Care and Use Committee (IACUC protocol \# IAC-15-000643).

Database Analyses {#sec5.6}
-----------------

All the gene expression datasets (besides the cancer cell line encyclopedia) in this study were from Oncomine ([www.oncomine.org](http://www.oncomine.org){#intref0010}) and were downloaded and analyzed using Oncomine premium research edition. The gene expression data in Oncomine is Log~2~ transformed and median-centered as in [Figures 1](#fig1){ref-type="fig"}C--1F, [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1G and [Figures S2](#mmc1){ref-type="supplementary-material"}G--S2I.

Statistical Considerations {#sec5.7}
--------------------------

IC~50~ values for cell lines as presented in [Figures 1](#fig1){ref-type="fig"}A and 1B were calculated as previously described in the drug screens ([@bib14]). Non-parametric Mann-Whitney U-tests were performed for [Figures 1](#fig1){ref-type="fig"}D and 1E and [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C. The statistical determinations from Table S1 are described in detail ([@bib63]). Student\'s *t* test (two-sided) and linear regression analysis were performed using GraphPad Prism. Differences were considered statistically different if p \< 0.05.
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![*MYCN*-Amplified Neuroblastoma Cells Have Sensitivity to the BCL-2/Bcl-xL Inhibitor ABT-263 and High NOXA Expression\
(A) The sensitivity of ABT-263 in neuroblastoma (NB) cell lines (n = 25) is plotted against other solid tumor cancer cell lines (n = 476). Student\'s t test.\
(B) Sensitivity of *MYCN*-amplified neuroblastomas (n = 16), *MYCN*-WT neuroblastomas (n = 9) and other solid tumor cancer cell lines (n = 476) to ABT-263. Student\'s t test.\
(C) Heatmap from data from [@bib59] showing RNA levels of MYCN and select BCL-2 family members from 20 *MYCN*-amplified and 81 *MYCN*-WT neuroblastomas. Arrow indicates NOXA (*PMAIP1*). The Oncomine Platform was used for analysis and visualization.\
(D) *PMAIP1* mRNA levels in 20 *MYCN*-amplified versus 81 *MYCN*-WT neuroblastoma. Non-parametric Mann-Whitney U-test, p \< 0.0001 ([@bib59]).\
(E) *PMAIP1* mRNA levels in stage 1--3 *MYCN*-WT (n = 51) versus stage 4 *MYCN*-WT (n = 30) neuroblastoma, non-parametric Mann-Whitney U-test, p \< 0.0001; stage 1--3 WT versus *MYCN*-amplified neuroblastoma, non-parametric Mann-Whitney U-test, p = 0.0188; and stage 4 WT versus *MYCN*-amplified neuroblastoma, non-parametric Mann-Whitney U-test, p \< 0.0001 ([@bib59]).\
(F) *PMAIP1* RNA expression plotted against *MYCN* RNA expression in 285 medulloblastoma tumors ([@bib43]). Linear regression analysis, R^2^ = 0.2167, p \< 0.0001. Red lines are the mean for (A), (B), (D), and (E) and error bars are ±SEM. Y axis is Log~2~ median-centered for (D) and (E), and both axes are Log~2~ median-centered for (F). See also [Figure S1](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![*MYCN*-Amplified Neuroblastoma Cells\' Sensitivity to ABT-263 Is Mitigated by NOXA Reduction\
(A and B) FACS apoptosis quantification of *MYCN*-amplified neuroblastoma cell lines SK-N-DZ (A) and SK-N-BE-2 (B) infected with scrambled (Sc) or NOXA-specific (NOXA) shRNA, n = 3, error bars are + SEM. Percent of apoptosis induced by ABT-263 minus the no treatment control. Inset = Western blot of knockdown.\
(C) Cell lysates from cells infected with a control shRNA (shSc) or shMYCN were immunoblotted for MYCN, NOXA, and β-ACTIN.\
(D and E) *MYCN*-WT neuroblastoma cells and the epithelium-derived RPE-1 cells were engineered to overexpress GFP or MYCN and lysates probed for MYCN, NOXA, or β-ACTIN (D), or levels of the abundance of *PMAIP1* RNA (E) (relative to *ACTB*). n = 3; error bars are +SD.\
(F and G) *MYCN*-WT cells expressing GFP or MYCN were left untreated or treated with ABT-263 for 24 hr and the amount of cleaved PARP determined (F), or for 72 hr and number of viable cells determined (G). For (G), n = 3. Error bars are +SD.\
(H and I) SK-N-BE(2) and SK-N-DZ shSC and shMYCN cells (as in (C)) were treated with ABT-263 for 72 hr and the amount of apoptosis was determined (H), or 72 hr and viable cells determined (I). For (I), n = 3. Error bars are +SD.\
(J) Ratio of SYBR green signal from a chromatin immunoprecipitation assay with an MYCN antibody over an isotype-matched IgG in the KELLY and SK-N-DZ cells (left) and schematic of the regions amplified on the *PMAIP1* promoter where MYCN bound (right). Error bars are + SD.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![*MYCN*-Amplified Neuroblastoma Cells Retains Sensitivity to ABT-199 through a High BCL-2/BCL-xL Ratio\
(A) *BCL2* (left), *BCL-xL* (middle), or the ratio of *BCL2*/*Bcl-xL* (right) from the Cancer Cell Line Encyclopedia were plotted for solid tumor cancer cell lines (n = 840) and neuroblastoma cell lines (n = 17). Student\'s t test, p \< 0.0001 for all comparisons. Red lines are means.\
(B) FACS apoptosis determination of indicated cell lines following 72 hr of ABT-199 or ABT-263 treatment over no-treatment control. Error bars are + SD, n = 3.\
(C) *MYCN*-WT neuroblastoma SK-N-SH, SK-N-F1, and the RPE-1 cells expressing GFP or MYCN were left untreated or treated with ABT-199 for 24 hr and the amount of cleaved PARP was determined.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Aurora A Inhibition Combines with ABT-199 to Promote Apoptosis and Induce Loss of Cell Viability\
(A and B) Anchor apoptosis drug screen with 1 μM ABT-199 and 24 other targeted therapies at two different doses (blue bars, 70 nM; red bars, 700 nM) in KELLY (A) and SK-N-DZ (B) cells. As controls, cells were also treated with no drug, 1 μM ABT-199 alone and 1 μM ABT-199 plus caspase inhibitor, as indicated. Blue dotted line drawn at amount of caspase activity from single-agent ABT-199 for visual comparison. Caspase activity is plotted on the y axis.\
(C) 72 hr viability assay of KELLY cells treated with increasing amounts of MLN8237 (left) or VX680 (right) in the absence or presence of 1 μM ABT-199.\
See also [Figures S4--S6](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![ABT-199/MLN8237 Is Effective in *MYCN*-Amplified Neuroblastoma Cells through Enhanced Apoptosis\
(A) FACS apoptosis determination of indicated cell line treated for 48 hr with the indicated treatments. Percent of apoptosis induced by the drugs minus the no treatment control. Error bars are SD (n = 3).\
(B) Western blot analysis of *MYCN*-amplified neuroblastomas treated with no drug (No Rx), MLN8237, ABT-199, or the combination.\
(C) SK-N-BE(2) cells transfected with scrambled (sc) siRNA, MCL-1 siRNA, or BIM siRNA were treated as indicated in the figure. FACS apoptosis is presented as the amount of apoptosis for each condition minus no treatment of the scrambled control. Error bars are +SEM.\
(D) Exogenous overexpression of MCL-1 in SK-N-BE(2) cells and PARP cleavage following combination treatment.\
(E) MCL-1 complex immunoprecipitation in the SK-N-BE(2) and SK-N-DZ cells. An IgG matched isotype antibody served as a control. Ratio of quantified band intensities of BIM complexed to MCL-1/normalized BIM amounts in the whole-cell lysates (WCLs).\
(F and G) Crystal violet staining of 5-day growth assays of *MYCN*-amplified (F) or *MYCN*-WT neuroblastoma cells or RPE-1 cells (G) left untreated (No Rx), or treated with MLN8237, ABT-199, or the combination.\
See also [Figures S4--S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![ABT-199/MLN8237 Is Effective in Mouse Models of *MYCN*-Amplified Neuroblastoma\
(A) Mice were treated with MLN8237, ABT-199, or both drugs for the indicated times. The cohort of KELLY mice treated with the combination was monitored for an additional 60 days. Error bars are + SEM.\
(B) Western blot analysis of tumor lysates from KELLY-bearing and SK-N-BE(2)-bearing mice with the indicated treatments (loading = GAPDH or β-actin).\
(C) SK-N-SH tumors were treated and monitored as in (A). Error bars are +SEM.\
(D) *MYCN*-WT neuroblastoma SK-N-SH, SK-N-F1, and the RPE-1 cells expressing GFP or MYCN were left untreated or treated with MLN8237/ABT-199 (combination) for 24 hr and lysates were blotted with the indicated antibodies.\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![ABT-199/MLN8237 Combination Is Effective at the Optimal Dosing Schedule of MLN8237 in *MYCN*-Amplified Neuroblastoma Models\
(A) NB-1643 mice were treated with single-agent MLN8237, single-agent ABT-199, or the combination and monitored for approximately 30 days. Error bars are +SEM.\
(B) All tumors from the combination cohort were monitored an additional 60 days and did not demonstrate re-growth.\
(C) Tumors (each represented by a bar) from individual mice bearing PDXs were monitored for growth after treatment with vehicle (control), MLN8237, ABT-199, or the combination for approximately 30 days.\
(D) Western blots from tumor lysates from the PDXs. Asterisk indicates non-specific band.\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}

![Schematic of *MYCN*-Amplified Neuroblastomas before and after Treatment with the ABT-199/MLN8237 Combination\
Asterisk denotes weak interaction due to low BCL-xL levels.\
In *MYCN*-amplified neuroblastoma, MYCN upregulates NOXA to inhibit MCL-1 and these tumors have low BCL-xL levels. The addition of ABT-199 inhibits BCL-2 with further reduction of MCL-1 by MLN8237, leading to the liberation of BIM and apoptosis. Modified from [@bib9].](gr8){#fig8}
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